Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case

IJU Case Reports

article

Mizuki Izawa¹  Takeo Kosaka¹  Kohei Nakamura²  Junna Oba²  Tomoyuki Hishida³  Hiroshi Hongo¹  Shuji Mikami⁴  Hiroshi Nishihara²  Mototsugu Oya¹ 

[1] Department of Urology, Keio University School of Medicine;Genomics Unit, Keio Cancer Center, Keio University School of Medicine;Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine;Division of Diagnostic Pathology, Keio University Hospital

关键词: abiraterone acetate;    BRCA2;    DNA damage repair genes;    next-generation sequencing;    prostate cancer;   

DOI  :  10.1002/iju5.12224

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Most metastatic prostate cancers acquire the capacity for androgen-independent growth and become resistant to androgen deprivation therapy. A patient-focused treatment strategy is needed for aggressive castration-resistant prostate cancer. Case presentation We report the case of a 62-year-old man who presented with prostatic adenocarcinoma who was treated by radiation and combined androgen blockade. After completion of first-line therapy, he was diagnosed with multiple metastatic castration-resistant prostate cancer in the lung. Second-line therapy with abiraterone acetate resulted in partial remission of the lung metastases. Thoracic surgery was performed to remove the single lung metastasis remaining. Next-generation sequencing of the specimens demonstrated homozygous loss of BRCA2 . We note in this case a heterogeneous response to abiraterone acetate may be related to the somatic BRCA2 deletions. Conclusions We present the first Japanese case of a metastatic abiraterone acetate-resistant castration-resistant prostate cancer accompanied by BRCA2 mutation.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND